Oncos Therapeutics granted orphan drug designation for CGTG-102 in soft tissue sarcoma (STS) by FDA and EMA

Oncos Therapeutics Ltd, a private, clinical-stage biotechnology company focused on the development and commercialization of targeted oncolytic immunotherapies for solid tumors, announced today that the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) have granted orphan drug designation for CGTG-102, a granulocyte-macrophage colony stimulating factor-coding oncolytic adenovirus (Ad5/3-D24-GMCSF) for the treatment of soft tissue sarcoma. "We are pleased to receive orphan drug designations for CGTG-102 from the two leading regulatory agencies in the world...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Regulatory Affairs / Drug Approvals Source Type: news